Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONA-255 in Advanced Breast and Gastric Cancer
2025-522233-62-00Phase 2Authorised
- Sponsor
- Ona Therapeutics
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ONA-255 in breast cancer, gastric adenocarcinoma, Esophago-Gastric Adenocarcinoma and 1 more, sponsored by Ona Therapeutics. Primary endpoints: Phase 1a: Dose-limiting toxicities, Phase 1a: Minimum biologically active dose (MBAD) and 2 more. Planned start Nov 2025; status: authorised.
02
Drugs
ONA-255
03
Conditions
breast cancergastric adenocarcinomaEsophago-Gastric Adenocarcinomacancer
Beyond the preview
Go deeper on 2025-522233-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522233-62-00.